VR Logo

NeuBase Therapeutics Inc. (NBSE) download report


Healthcare | Biotechnology & Pharma Research

NeuBase Therapeutics Inc. (NBSE) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.

IPO Date: 01-May-2007

Founder, Pres, CEO & Chairman: Dr. Dietrich A. Stephan Ph.D.

Chief Operating Officer: Dr. William Roland Mann MBA, Ph.D.

Listing: NASDAQ: NBSE

Country: United States

Headquarters: Pittsburgh, PA

Website: https://www.neubasetherapeutics.com

Key Facts

Market cap: $28.39 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-33.47 Mln

Cash: $38.96 Mln

Total Debt: $6.32 Mln

Insider's Holding: 8.69%

Liquidity: Low

52 Week range: $0.77 - 4.91

Shares outstanding: 32,258,700

10 Years Aggregate:

  • CFO: $-97.70 Mln
  • EBITDA: $-156.59 Mln
  • Net Profit: $-164.00 Mln

Stock Performance

Time Period NeuBase Therapeutics (NBSE) S&P BSE Sensex S&P Small-Cap 600
YTD-66.05-8.97-19.67
1 month-6.47-3.38-9.84
3 months-48.98-7.93-15.05
1 Year-81.260.55-18.10
3 Years-34.6010.415.71
5 Years-40.3211.455.53
10 Years--12.0510.04
As on 29-Jun-2022
Year NeuBase Therapeutics (NBSE) S&P Small-Cap 600 S&P BSE Sensex
2021-59.8025.2721.99
2020-2.929.5715.75
2019318.6020.8614.38
2018-95.30-9.705.87
201724.0011.7327.91
2016-75.5724.741.95
2015-26.38-3.36-5.03